GC Pharma (Formerly known as Green Cross)

22 articles with GC Pharma (Formerly known as Green Cross)

• GC Pharma Reports Full Year 2018 Results

  2/12/2019

  GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2018.

• CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome

  1/7/2019

  CANbridge Pharmaceuticals Inc. announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome.

• GC Pharma Reports Q3 2018 Results

  10/30/2018

  GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the three months ended September 30, 2018.

• GC Pharma Receives Korea's MFDS Approval of GCFLU Quadrivalent (Influenza Vaccine) for persons 6 months and older

  10/1/2018

  GC Pharma announced today it has received approval from the South Korean Ministry of Food and Drug Safety (MFDS) expanding the indication for GCFLU Quadrivalent™ (Seasonal Influenza Vaccine) to include use in persons 6 months and older. Prior to this, the vaccine was approved for use in persons 3 years of age and older.

• GC Pharma Reports Q2 2018 Results

  8/1/2018

  Q2 Performance was In-line with Expectations

• GC Pharma Reports Q1 2018 Results

  4/27/2018

  GC Pharma announced unaudited results for the three months ended March 31, 2018.

• GC Pharma and Lee's Pharm Enter Into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

  2/14/2018

  Under the terms of the agreement, Lee's Pharm receives exclusive rights to develop and commercialise the anticoagulant for the greater China and South East Asian market.

• GC Pharma Reports Full Year 2017 Results

  2/5/2018

  GC Pharma (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2017.

• GC Pharma Confirms Phase I/III Clinical Trial of New Protein Therapy for Hepatitis B

  1/18/2018

  The clinical 2/3 trial is expected to take around 5 years to complete, with patient enrollment beginning in early 2018.

• Green Cross Receives Complete Response Letter From US FDA For IVIG-SN

  11/23/2016

• US FDA Accepts Green Cross' Biologics License Application For IVIG-SN

  1/26/2016

• Green Cross To Build Cell Therapy Manufacturing Facility In China

  4/29/2015

• Green Cross To Form Cell Therapy Company In China

  3/16/2015

• President Of Leading South Korean Biopharmaceutical Company Green Cross Joins Stemedica Cell Technologies, Inc.'s Board Of Directors

  4/22/2014

• Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia

  8/9/2012

• Green Cross Gains Market Approval With the World's 2nd Orphan Drug for Hunter Syndrome in South Korea

  1/27/2012

• Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer

  4/21/2011

• Biocryst Pharmaceuticals Partner Green Cross Receives Marketing & Manufacturing Approval for Peramivir in South Korea

  8/16/2010

• Biocryst Pharmaceuticals's Partner Green Cross Files for Peramivir Regulatory Approval in South Korea

  1/8/2010

• Abraxis BioScience, Inc. Announces Agreement with Green Cross for the Commercialization of ABRAXANE in Korea

  11/28/2007